Clinical trials: Toxicity, open to volunteers
Xiao Chai Hu Tang, Irinotecan-induced Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide…
- Trial name
- NCT06055179
- Testing
- Xiao Chai Hu Tang (XCHT), Irinotecan regimen, Raloxifene
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Cancer Related Cardiovascular Toxicity
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of…
- Trial name
- NCT06086132
- Testing
- Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
- Where
- 5 sites in Italy, North Macedonia and 1 more
- Volunteers
- 10,000 people
- Sponsor
- University of Bologna
Lymphoma, Physical Exercise
Effects of Exercise Training in Survivors of Lymphoma
This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and…
- Conditions
- Lymphoma, Physical Exercise, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- LYMfit (NCT06270667)
- Testing
- Aerobic Exercise, Combined Aerobic and Resistance Exercise
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Norwegian School of Sport Sciences
Breast Cancer, Drug-Related Side Effects and Adverse Reactions
Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients
This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy.
- Conditions
- Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Chemotherapy Toxicity, Treatment Adherence
- Trial name
- NCT07524829
- Testing
- Structured Telenursing Follow-up, Standard Nursing Care
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Azienda Sanitaria Locale di Asti
Breast Cancer
Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer
The study is a single-center, prospective, non-randomized controlled study. The primary objective is to examine the clinical outcomes of utilizing Deep Inspiration Breath Hold (DIBH) in conjunction with hypo-fractionated…
- Trial name
- DLLEB (NCT06660628)
- Testing
- Large Segmentation Radiotherapy, DIBH, Surface guided radiation therapy
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers
Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
This is a multicenter Phase 1b/2 clinical trial investigating the efficacy and safety of a combination regimen of Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab in treatment-naïve patients with unresectable, locally…
- Trial name
- GENTIS (NCT06893380)
- Testing
- Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- CHA University
Prostate Cancer, Biochemical Recurrence
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy
Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a…
- Conditions
- Prostate Cancer, Biochemical Recurrence, Radiation, Hypofractionation
- Trial name
- SHARE (NCT03920033)
- Testing
- Salvage radiation therapy
- Where
- 2 sites in South Korea
- Volunteers
- 288 people
- Sponsor
- Asan Medical Center
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head.
- Conditions
- Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma
- Trial name
- NCT06406465
- Testing
- Belinostat, Cisplatin, Etoposide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Oral Mucositis, Quality of Life
Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.
The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- STOPOMP (NCT05635929)
- Testing
- XCM-OM118 Composition comprising olive oil, betaine and xylitol
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- Mucosa Innovations, S.L.
Breast Cancer, Metastatic Breast Cancer
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
The metabolism of anticancer drugs is influenced by genetic variants that affect their bioavailability and toxicity. In the case of antibody-drug conjugates (ADCs), such as sacituzumab-govitecan (SG), trastuzumab-deruxtecan…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetic Variant
- Trial name
- NCT07582887
- Testing
- Sacituzumab Govitecan, Trastuzumab deruxtecan, Datopotamab Deruxtecan
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Cytokine Release Syndrome, ICANS
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
This Phase I, prospective, single-arm clinical study aims to evaluate the efficacy and safety of adjunctive methylene blue (MB) in patients experiencing cytokine release syndrome (CRS) or immune effector cell-associated…
- Trial name
- NCT07169487
- Testing
- Methylene Blue
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cancer, Oncology
Longitudinal Registry Including Patients Treated With Heavy Particles
The purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO)…
- Conditions
- Cancer, Oncology, Radiation Exposure, Radiotherapy Side Effect
- Trial name
- NCT05203250
- Testing
- Heavy-ion therapy (hadrontherapy)
- Where
- Italy
- Volunteers
- 3,000 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML)…
- Trial name
- NCT04243785
- Testing
- BTX-A51, Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Edgewood Oncology Inc.
Melanoma
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
This phase I trial studies the side effects of adding anakinra and tocilizumab to standard treatment with nivolumab and ipilimumab and to see how well it works in treating melanoma patients who are 50 years of age or older.
- Trial name
- NCT07838974
- Testing
- Anakinra, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Cervical Cancer, Gynecologic Cancer
MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)
The goal of this observational study is to explore the effectiveness and side effects of a high dose daily adapted SBRT (stereotactic body radiotherapy) boost delivered with MRLinac in patients with gynaecological cancers that…
- Trial name
- MARGARITA (NCT05937958)
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Multiple Myeloma, Multiple Myeloma in Relapse
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT07200089
- Testing
- NT-I7
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT06183268
- Testing
- Spot Delete
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Covenant Health Cancer Center
Advanced Renal Cell Carcinoma (aRCC)
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Introduction: This document explains a clinical research study conducted at Peking Union Medical College Hospital. The study aims to evaluate a new combination treatment - Envafolimab (an immunotherapy) and Axitinib (a targeted…
- Trial name
- NCT07159191
- Testing
- Envafolimab Injection, Axitinib Tablets
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Melanoma
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune…
- Trial name
- NCT07660666
- Testing
- Electronic Health Record Review, Internet-Based Intervention, Patient Navigation
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Acute Kidney Injury, Cancer
Cisplatin Induced Kidney Toxicity
Cisplatin (CisP) is a chemotherapeutic agent used to treat head and neck and lung cancer in adults and over 15 different pediatric cancers.
- Trial name
- ACCENT (NCT04442516)
- Testing
- Questionnaire, sampling of blood, urine and saliva
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- The Hospital for Sick Children